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Adjuvant therapy aims to prevent outgrowth of residual disease but can induce serious side effects. Weighing conflicting treatment
effects and communicating this information with patients is not elementary. This study presents a scheme balancing benefit and harm
of adjuvant therapy vs no adjuvant therapy. It is illustrated by the available evidence on adjuvant pelvic external beam radiotherapy
(RT) for intermediate-risk stage I endometrial carcinoma patients. The scheme comprises five outcome possibilities of adjuvant
therapy: patients who benefit from adjuvant therapy (some at the cost of complications) vs those who neither benefit nor contract
complications, those who do not benefit but contract severe complications, or those who die. Using absolute risk differences, a fictive
cohort of 1000 patients receiving adjuvant RT is categorised. Three large randomised clinical trials were included. Recurrences will be
prevented by adjuvant RT in 60 patients, a majority of 908 patients will neither benefit nor suffer severe radiation-induced harm but
28 patients will suffer severe complications due to adjuvant RT and an expected four patients will die. This scheme readily summarises
the different possible treatment outcomes and can be of practical value for clinicians and patients in decision making about adjuvant
therapies.
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Adjuvant therapy aims to prevent outgrowth of residual disease
after surgical removal of a malignancy to improve disease-specific
and overall survival. However, adjuvant therapy can induce serious
side effects as well. Therefore, the benefit of adjuvant therapy in
terms of a reduced risk of recurrence needs to be weighed carefully
against the risk of therapy-induced harm, before a decision is
made.
Particularly when the effect of available treatment options is
ambiguous or equal, patient preferences can play a crucial role in
decision making. In a recent study by Pieterse et al (2007), the
deciding benefit to choose for neoadjuvant radiotherapy (RT) and
the importance of different treatment outcomes were found to vary
widely among rectal cancer patients as well as between oncologists
and patients. Moreover, oncology patients were found to be more
than willing to participate in decision making after being
thoroughly informed (van Tol-Geerdink et al, 2006). Clinicians
should therefore adequately inform their patients about the risks
and benefits of adjuvant therapy, and elicit patient preferences
regarding treatment outcomes.
It is not elementary to weigh conflicting treatment effects and to
communicate this information with patients. Parameters such as
number needed to treat (NNT) and number needed to harm
(NNH) have been proposed to give the clinician some direction of
the benefit and harm of adjuvant therapies. However, they often
over-simplify the consequences of a treatment (Nuovo et al, 2002;
Massel, 2003). For example, NNT does not differentiate between
patients in whom a recurrence is prevented without suffering side
effects and patients who are spared from a recurrence but who do
suffer serious side effects. Thus, these rather intangible numbers
cannot express how many patients will benefit or suffer from the
adjuvant therapy.
In intermediate-risk stage I endometrial carcinoma, for instance,
adjuvant pelvic external beam RT is presently the acknowledged
treatment to reduce the risk of outgrowth of residual disease in the
pelvis (http://www.guideline.gov/summary/summary.aspx?doc_id¼
9203&nbr¼004957&string¼endometrial+AND+cancer). Neverthe-
less, a great international controversy exists (Burger, 2001; Johnson
and Cornes, 2007). In a recent meta-analysis, the benefits of adjuvant
RT were reviewed. In the subgroup of intermediate-risk patients, a
statistically significant reduction of local recurrences was observed
when adjuvant RT was applied compared with no adjuvant therapy
following surgery (NNT 16.7 women; 95% confidence interval 12.5–
25.0). However, this advantage did not result in a better overall
or endometrial carcinoma-related survival for these patients (Kong
et al, 2007). No clear recommendations for clinical practice were
given based on these results.
A plain scheme presenting (the risk of) all possible out-
comes of adjuvant therapy could provide more insights for
clinicians as well as for patients. Such a tool has been designed
earlier with respect to neoadjuvant RT for resectable rectal
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scarcinomas (Bakx et al, 2006). Yet, this has not been recognised
as a useful tool to facilitate clinician–patient communication when
vacillating about the decision for (neo)adjuvant cancer therapy.
The aim of this study is to present a scheme balancing the benefit
and harm of adjuvant therapy vs no adjuvant therapy, illustrated by
the available evidence on adjuvant pelvic external beam RT for
intermediate-risk stage I endometrial carcinoma patients.
MATERIALS AND METHODS
The scheme comprises five outcome possibilities of adjuvant therapy,
ranging from patients experiencing full benefit without any harm to
patients experiencing full harm, that is death from adjuvant therapy
(Table 1). Presenting these different outcome possibilities in natural
frequencies is not yet very common, but helpful (Hoffrage et al,
2000). Therefore, evidence on the beneficial and harmful effects of
adjuvant RT was needed to enter data into the scheme.
All available relevant evidence was searched in PubMed, and
studies were included if they comprised (1) randomised clinical trials
(RCTs), (2) comparing adjuvant pelvic external beam RT following
surgery vs surgery alone and (3) in women with stage 1 intermediate-
risk endometrial carcinoma. Local recurrences and RT-induced harm
had to be one of the clinical end-points measured.
The extent of benefit and harm in the included studies was
determined by means of the absolute risk reduction (ARR) and
absolute risk increase (ARI) (McAlister et al, 2000; Straus, 2002).
Treatment benefit can be expressed as an ARR. This expresses the
absolute additional beneficial effect of adjuvant therapy over no
adjuvant treatment and is equal to the difference between control
event rate and experimental event rate found in RCTs (ARR¼
event rate control group event rate intervention group). The
ARR can also be calculated as the reciprocal of NNT, which is
commonly used to express the number of patients who needs to be
treated to gain one additional beneficial outcome. For instance, an
NNT of 5 corresponds to an ARR of 1/5¼0.2.
Although survival is considered to be the ultimate primary
outcome in oncology trials, the available RCTs considering adju-
vant RT in stage I intermediate-risk endometrial cancer patients
have shown neither overall survival benefit nor endometrial-
carcinoma-related survival advantage. Hence, in this analysis, we
chose local recurrence rate (ARRlocal recurrence) as the primary
outcome parameter. Preventing local recurrences is relevant if it
increases the rate of cancers cured and if it avoids the women’s
mental and physical morbidity of additional diagnosis and
treatment (Creutzberg et al, 2000).
The ARI is a measure of treatment-induced harm. It is defined
by the absolute difference in complication rates between two
treatment modalities (ARI¼complication rate intervention group-
complication rate control group). The ARI can also be calculated
as the reciprocal of NNH, which is used to express the number of
patients who has to undergo treatment to induce one additional
harmful event. In this analysis, the ARI was the difference between
the complication rates of women with and without adjuvant RT.
Complication rates involved morbidity and mortality, resulting in
ARImorbidity and ARImortality.
Although mortality is a clear-cut end-point, morbidity may be
subject to discussion regarding the level of severity. In this
analysis, only severe grade 3 complications, according to the
French–Italian glossary, were taken into account (Chassagne et al,
1993), because the severity of these complications could cause
women to reconsider their decision about having adjuvant RT.
Grade 3 complications are life-threatening per se or due to their
treatment required. They also comprise any permanent and
severe tissue or organ damage (e.g., stenosis, bleeding, or fistulas
of the intestines or of the urinary tract). Grade 4 complications
are deaths due to a complication of the treatment of cancer,
comprising ARImortality.
From the included studies, the reported number of study
participants in the RT and control groups, the number of local
recurrences, severe complications and deaths due to adjuvant RT
were extracted (Table 2). These were combined into an overall
ARR, overall ARI for morbidity and overall ARI for mortality. A
95% CI was determined to provide an estimate of the precision of
the ARR and ARIs.
Subsequently, patients receiving adjuvant RT were divided into
five outcome groups based on the benefit and harm the therapy
may induce. As using absolute numbers and stating the reference
class is likely to improve the understanding of risks and benefits
(Gigerenzer and Edwards, 2003), this is illustrated in a fictive
cohort of 1000 women receiving adjuvant RT. It is worth noting
that the ‘benefit’ in this analysis is about the difference in local
recurrence rates between the two treatment modalities, whereas
‘harm’ in this scheme concerns the difference in complication
rates. Table 1 gives the equations to calculate each of the five
groups (Schulzer and Mancini, 1996; Mancini and Schulzer, 1999).
RESULTS
Six RCTs, studying adjuvant pelvic external beam RT vs no
adjuvant therapy in early-stage endometrial carcinoma, were
identified (Aalders et al, 1980; Weigensberg, 1984; Creutzberg
et al, 2000; Soderini et al, 2003; Keys et al, 2004; the ASTEC/EN.5
writing committee 2008, 2009). One RCT was excluded because the
control group underwent another adjuvant intervention instead of
no intervention (Aalders et al, 1980). The clinical trial of
Weigensberg (1984) focussed on preoperative RT (Weigensberg,
1984). The study of Soderini et al (2003) (published as an abstract
only) did not report radiation-induced harm, and was therefore
also excluded from analysis (Soderini et al, 2003).
Three large RCTs remained: the Post Operative Radiation
Therapy in Endometrial Carcinoma-1 study from Creutzberg
(PORTEC-1), the Gynecologic Oncology Group 99 study from
Keys (GOG 99) and A Study in the Treatment of Endometrial
Cancer/EN.5 study from the ASTEC/EN.5 writing committee 2008
Table 1 Five groups of possible outcomes after adjuvant RT
Group Definition in this analysis Equation
1: Full benefit, no harm Patients in whom RT prevented the development of a local recurrence and who do not suffer
from morbidity due to RT
ARR (1 ARImorbidity)
2: Benefit with harm Patients in whom RT prevented the development of a local recurrence, but suffer from
morbidity induced by RT
ARR ARImorbidity
3: Neither benefit
nor harm
Patients in whom RT did not prevent a local recurrence, but do not suffer from RT-related
morbidity
(1 ARR) (1 (ARImorbidity+ARImortality))
4: No benefit but harm Patients in whom RT did not prevent a local recurrence, and suffer from morbidity due to RT (1 ARR) ARImorbidity
5: Full harm Patients who die as a result of RT ARImortality
ARImorbidity¼absolute risk increase in radiation-induced morbidity; ARImortality¼absolute risk increase in radiation-induced mortality; ARR¼absolute risk reduction in the
development of local recurrences; RT¼radiotherapy.
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EN.5 writing committee 2008, 2009). They comprised 2011 women,
and relevant data on benefit and harm in the intervention and
control groups could be extracted (Table 2).
All studies were of a randomised design, compared the same
interventions (adjuvant pelvic external beam RT vs no adjuvant
therapy) and reported the required outcome measures (local
recurrence rate and treatment-induced harm) on similar patients
(intermediate-risk stage I endometrial cancer patients). In the
ASTEC/EN.5 trial, brachytherapy was also allowed if the centre’s
policy was to offer it to all International Federation of Gynecology
and Obstetrics (FIGO) stage I or IIA women irrespective of RT
allocation. Similar proportions of women in the RT group as well
as the control group received brachytherapy (52 and 51%,
respectively). Providing brachytherapy might lead to an under-
estimation of the beneficial effect of adjuvant external RT and an
overestimation of the risk of complications of adjuvant RT for
stage I intermediate-risk endometrial cancer patients. However,
sensitivity analyses showed that the numbers in the model hardly
changed when only the PORTEC-1 and GOG 99 trials were taken
into account (ARR 0.09, ARImorbidity 0.04 and ARImortality 0.005).
All in all, we decided that the data of these three studies could be
used to calculate an overall ARR and ARI to complete our scheme.
Subsequently, the overall ARR and ARIs were combined by
means of the equations in Table 1 to compose the five possible
outcome groups. This is illustrated in a fictive cohort of 1000
women receiving adjuvant RT for their stage 1 intermediate-risk
endometrial carcinoma (Figure 1). This shows that from a putative
cohort of 1000 patients, adjuvant RT will prevent recurrences in 60
patients (groups 1 and 2), a majority of 908 patients will neither
Table 2 Results of the included trials and overall risk differences
n Local recurrences (%) Severe morbidity (%) Mortality (%)
PORTEC-1
Radiotherapy 354 11 (0.03) 6 (0.02) 1 (0.003)
Control 360 40 (0.11) 1 (0.003) 0 (0.00)
GOG 99
Radiotherapy 190 3 (0.02) 9 (0.05) 2 (0.01)
Control 202 18 (0.09) 1 (0.005) 0 (0.00)
ASTEC/EN.5
Radiotherapy 452 13 (0.03) 34 (0.08) 1 (0.002)
Control 453 29 (0.06) 15 (0.03) 0 (0.00)
Overall
Radiotherapy 996 27 (0.03) 49 (0.05) 4 (0.004)
Control 1015 87 (0.09) 17 (0.02) 0 (0.000)
Risk difference (95% CI) 2011 ARR: 0.06 (0.04–0.08) ARImorbidity: 0.03 (0.02–0.05) ARImortality: 0.004 (0.000–0.008)
ARImorbidity¼absolute risk increase in radiation-induced morbidity; ARImortality¼absolute risk increase in radiation-induced mortality; ARR¼absolute risk reduction in the
development of local recurrences. 95% CI¼95% confidence interval. Bold represent the pooled estimates of the three studies described above (PORTEC-1, GOG99
and ASTEC/EN.5).
Beneficial: local reccurence prevented by RT∗
1. Full benefit, no harm:
Patients in whom RT
prevented the development of
a local recurrence and who
do not suffer from severe
complications due to RT
2. Benefit with harm:
Patients in whom RT
prevented the development 
of a local recurrence, but
suffer from severe
complications
3. Neither benefit nor harm:
Patients in whom RT neither
prevente a local recurrence
nor induced severe
complications
4. No benefit, but harm:
Patients in whom RT did
not a prevent local
recurrence and suffer from
severe complications due
to RT
5. Full harm:
Patients who die as
a result of RT
Not beneficial: local recurrence not prevented by RT∗
940 60
58 2 908 28 4
Pateints receiving adjuvant RT
1000
Figure 1 Benefit and harm for a fictive cohort of 1000 irradiated patients in whom adjuvant RT is compared with no adjuvant treatment. *This figure
displays the differences between adjuvant RT and no adjuvant therapy rather than absolute frequencies, that is the additional benefit in terms of local
recurrences as prevented by adjuvant RT and the additional harm in terms of severe complications and deaths as induced by adjuvant RT.
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sbenefit nor suffer severe radiation-induced harm (group 3), but 28
patients will suffer severe complications due to adjuvant RT
(group 4) and an expected four patients will die (group 5).
DISCUSSION
In this study, a scheme is presented to balance the benefit and
harm of adjuvant therapy vs no adjuvant therapy. To exemplify
this scheme, we utilised the data on adjuvant pelvic external beam
RT for intermediate-risk stage I endometrial carcinoma patients.
The scheme readily provides an insight into the proportion of
patients who will benefit from adjuvant therapy (some at the cost
of complications) versus those who neither benefit nor contract
complications, and those who do not benefit from adjuvant
therapy but do contract severe complications, or even die.
It may be hard to imagine that providing an adjuvant therapy
does not necessarily lead to the intended effect and can even harm
our patients. However, as complications might harm patients who
do not have any benefit from adjuvant therapy, we advocate the
evidence as presented in this scheme to be communicated to them.
This will enable patients to determine their preference regarding
adjuvant therapy based on comprehensive information, which
ultimately facilitates shared decision making (Charles et al, 1997;
van Tol-Geerdink et al, 2008).
In our example of intermediate-risk stage I endometrial
carcinoma patients, here is what one could communicate about
adjuvant RT based on the insight provided by the completed
scheme. The patient should first be informed about the risk of
developing a local recurrence, that is about 10% according to our
included studies. Providing adjuvant RT will not improve the
patient’s chances of survival, but does decrease the risk of
developing a local recurrence. Along with communicating the
probability of developing a local recurrence, one should try and
explain to the patient what it is like to experience this.
Subsequently, our scheme may be used by clinicians to explain
that in a group of 1000 patients like them, if they would undergo
postoperative RT, the majority (908) will neither benefit from RT
in terms of prevented local recurrences, nor suffer from severe
complications. The physical and mental discomfort of a local
recurrence will be prevented in 60 patients, whereas serious,
sometimes even life-threatening, complications from RT will occur
in 28 patients, and an expected four patients will die. An
explanation of what it would be for the patient to experience
severe complications is needed, and it should be stressed that
severe complications are included in the scheme (because these
complications could cause them to reconsider having RT or not),
but moderate and mild complications are not.
By means of this scheme, benefit and harm of two adjuvant
therapies, or an adjuvant therapy versus no adjuvant treatment,
can be balanced. Although this provides a convenient and
orderly overview, the scheme is of less value in case more
adjuvant therapies are available. For example, for stage I
intermediate-risk endometrial cancer patients, vaginal intra-
cavitary brachytherapy is currently hypothesised to be superior
to external RT in terms of morbidity and mortality due to its local
rather than regional effect (http://www.trialregister.nl/trialreg/
admin/rctview.asp?TC¼332). These two adjuvant therapies could
be compared in a scheme as presented in this paper; however, the
option of providing no adjuvant treatment cannot be incorporated
in the same scheme. This leads to three separate schemes
comparing: (1) external beam RT vs no adjuvant therapy, (2)
brachytherapy vs no adjuvant therapy and (3) external beam RT vs
brachytherapy, which is far too complicated to gain a view of the
situation.
As the development of local recurrences is nowadays considered
to be the primary end-point in studies of adjuvant RT, we chose
local recurrence rate as the primary end-point in our scheme as
well. However, we realise that this is an intermediate end point as it
does not include subsequent benefit and harm of therapy after the
development of a recurrence. Salvage therapy includes surgery,
external beam RT and intracavitary RT, and is experienced as
physically extremely uncomfortable and mentally very stressful,
causing a substantial decrease in quality of life. Survival after
relapse is significantly better in patients who have not received
adjuvant RT than in those who already did (3-year survival 51 vs
19% (P¼0.004)) (Creutzberg et al, 2003). However, this does not
lead to a better overall survival in patients without adjuvant RT. In
the scheme presented, it was impossible to incorporate the
morbidity and mortality of treating a local recurrence by means
of salvage therapy, although it is likely that the clinical bottom line
would hardly change due to the great share of patients receiving
neither benefit nor harm from adjuvant RT. When deciding about
adjuvant RT, patients should therefore also be informed about the
procedure of salvage therapy and the differences in survival after
relapse.
The scheme as presented in this paper readily summarises the
different possible treatment outcomes and can be of practical value
for clinicians as well as for patients in (shared) decision making
about adjuvant therapies. Moreover, it can be, and has already
been in a few instances, generalised towards other interventions in
other medical specialties, when pros and cons need to be weighed
to make a treatment decision. Future research should reveal if
clinicians as well as patients evaluate this scheme as a valuable tool
to balance benefit and harm and whether it affects their final
treatment decision.
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